Q-omics provides the consensus-scored BCKDHB profile across patient tissues and cancer cell-line models. BCKDHB expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, BCKDHB is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, BCKDHB protein abundance shows 30,840 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight CHOL, KIRC, and PDAC as cancer lineages where BCKDHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCKDHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCKDHB survival associations across molecular data types. BCKDHB RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCKDHB RNA expression–survival associations across cancer types. High BCKDHB expression shows unfavorable associations in CHOL, but favorable associations in KIRC, READ, ACC, LAML and SKCM. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CHOL as the clearest survival context for BCKDHB RNA expression.
This table summarizes BCKDHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BCKDHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCKDHB shows lower tumor expression in KIRC, THCA, LIHC, KICH, BRCA and CHOL. The KIRC box plot shows higher BCKDHB RNA expression in normal versus tumor tissue (log2 FC = −1.262, t-test p < 0.001).
This table shows molecular features associated with BCKDHB in patient tissues and cancer cell lines. In patient samples, BCKDHB shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCKDHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
